209 related articles for article (PubMed ID: 18154212)
21. The risk of nail changes with epidermal growth factor receptor inhibitors: a systematic review of the literature and meta-analysis.
Garden BC; Wu S; Lacouture ME
J Am Acad Dermatol; 2012 Sep; 67(3):400-8. PubMed ID: 22088429
[TBL] [Abstract][Full Text] [Related]
22. The development of a Functional Assessment of Cancer Therapy (FACT) questionnaire to assess dermatologic symptoms associated with epidermal growth factor receptor inhibitors (FACT-EGFRI-18).
Wagner LI; Berg SR; Gandhi M; Hlubocky FJ; Webster K; Aneja M; Cella D; Lacouture ME
Support Care Cancer; 2013 Apr; 21(4):1033-41. PubMed ID: 23128934
[TBL] [Abstract][Full Text] [Related]
23. Cutaneous adverse effects during therapy with an epidermal growth factor receptor (EGFR) inhibitor.
Santoro F; Cozzani E; Parodi A
J Dermatolog Treat; 2006; 17(3):160-1. PubMed ID: 16854757
[TBL] [Abstract][Full Text] [Related]
24. Clinical research of EGFR inhibitors and related dermatologic toxicities.
Perez-Soler R; Van Cutsem E
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):10-6. PubMed ID: 18154213
[TBL] [Abstract][Full Text] [Related]
25. Description and management of cutaneous side effects during erlotinib and cetuximab treatment in lung and colorectal cancer patients: a prospective and descriptive study of 19 patients.
de Noronha e Menezes NM; Lima R; Moreira A; Varela P; Barroso A; Baptista A; Parente B
Eur J Dermatol; 2009; 19(3):248-51. PubMed ID: 19258241
[TBL] [Abstract][Full Text] [Related]
26. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors.
Galimont-Collen AF; Vos LE; Lavrijsen AP; Ouwerkerk J; Gelderblom H
Eur J Cancer; 2007 Mar; 43(5):845-51. PubMed ID: 17289377
[TBL] [Abstract][Full Text] [Related]
27. Clinical management of EGFRI-associated dermatologic toxicities: pharmacy perspective.
Iacovelli L
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):31-3. PubMed ID: 18154216
[TBL] [Abstract][Full Text] [Related]
28. Clinical management of EGFRI dermatologic toxicities: the Japanese perspective.
Yamazaki N; Muro K
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):27-8. PubMed ID: 18159648
[TBL] [Abstract][Full Text] [Related]
29. Adverse cutaneous reactions to epidermal growth factor receptor inhibitors: a study of 14 patients.
Santiago F; Gonçalo M; Reis JP; Figueiredo A
An Bras Dermatol; 2011; 86(3):483-90. PubMed ID: 21738965
[TBL] [Abstract][Full Text] [Related]
30. Acneiform eruptions induced by epidermal growth factor receptor inhibitors: treatment with oral isotretinoin.
Requena C; Llombart B; Sanmartín O
Cutis; 2012 Aug; 90(2):77-80. PubMed ID: 22988651
[TBL] [Abstract][Full Text] [Related]
31. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
32. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
33. Clinical management of cutaneous toxicity of anti-EGFR agents.
Monti M; Motta S
Int J Biol Markers; 2007; 22(1 Suppl 4):S53-61. PubMed ID: 17520582
[TBL] [Abstract][Full Text] [Related]
34. EGFR-targeted therapy and related skin toxicity.
Morse L; Calarese P
Semin Oncol Nurs; 2006 Aug; 22(3):152-62. PubMed ID: 16893744
[TBL] [Abstract][Full Text] [Related]
35. Re: Cetuximab therapy and symptomatic hypomagnesemia.
Altundag K; Altundag O; Baptista MZ; Turen S; Atik MA
J Natl Cancer Inst; 2005 Dec; 97(23):1791-2. PubMed ID: 16333039
[No Abstract] [Full Text] [Related]
36. Targeting the epidermal growth factor receptor in colorectal carcinoma.
Kurtin SE
Cancer Nurs; 2007; 30(4 Suppl 1):S1-9. PubMed ID: 17666985
[TBL] [Abstract][Full Text] [Related]
37. Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors.
Tan EH; Chan A
Ann Pharmacother; 2009 Oct; 43(10):1658-66. PubMed ID: 19755624
[TBL] [Abstract][Full Text] [Related]
38. Nondermatologic adverse events associated with anti-EGFR therapy.
Sandler AB
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 2):35-40. PubMed ID: 16736981
[TBL] [Abstract][Full Text] [Related]
39. Clinical management of EGFRI dermatologic toxicities: the nursing perspective.
Purdom M; Ohinata A
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):29-30. PubMed ID: 18154215
[TBL] [Abstract][Full Text] [Related]
40. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Lacouture ME; Maitland ML; Segaert S; Setser A; Baran R; Fox LP; Epstein JB; Barasch A; Einhorn L; Wagner L; West DP; Rapoport BL; Kris MG; Basch E; Eaby B; Kurtin S; Olsen EA; Chen A; Dancey JE; Trotti A
Support Care Cancer; 2010 Apr; 18(4):509-22. PubMed ID: 20145956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]